These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


631 related items for PubMed ID: 16886969

  • 1. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [Abstract] [Full Text] [Related]

  • 2. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC, Lugao HB, Pereira MC, Machado HR, Castro Md, Moreira AC.
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [Abstract] [Full Text] [Related]

  • 3. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM.
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [Abstract] [Full Text] [Related]

  • 4. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

  • 5. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA, Miell JP, Chambers SM, McGregor AM, Aylwin SJ.
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism.
    Díez JJ, Grande C, Méndez J, González-Gancedo P, Iglesias P.
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):27-34. PubMed ID: 16817815
    [Abstract] [Full Text] [Related]

  • 7. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D, Barreca A.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [Abstract] [Full Text] [Related]

  • 8. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
    Kim EH, Oh MC, Lee EJ, Kim SH.
    Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
    [Abstract] [Full Text] [Related]

  • 9. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
    Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM.
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
    [Abstract] [Full Text] [Related]

  • 10. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC, Rossi A, Martinelli CE, Machado HR, Moreira AC.
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU, Post KD, Powell JS, Wardlaw SL.
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [Abstract] [Full Text] [Related]

  • 12. Homocysteine levels in acromegaly patients.
    Hekimsoy Z, Ozmen B, Ulusoy S.
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P, Hildebrandt G, Schaeffer HJ, Schönau E, Klug N.
    Exp Clin Endocrinol Diabetes; 1998 Dec; 106(2):130-4. PubMed ID: 9628244
    [Abstract] [Full Text] [Related]

  • 14. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
    Levitt NS, Ratanjee BD, Abrahamson MJ.
    Horm Metab Res; 1995 Apr; 27(4):185-8. PubMed ID: 7750902
    [Abstract] [Full Text] [Related]

  • 15. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice.
    Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ.
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):65-70. PubMed ID: 17437512
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of suppression of growth hormone levels following a 75g oral glucose tolerance test.
    Nazaimoon WM, Ng ML, Satgunasingam N, Khalid BA.
    Med J Malaysia; 1992 Jun; 47(2):103-9. PubMed ID: 1494329
    [Abstract] [Full Text] [Related]

  • 17. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O, Beauregard C, Hardy J.
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [Abstract] [Full Text] [Related]

  • 18. Are there alternative tests for diagnosis of acromegaly?
    Popovic V.
    J Endocrinol Invest; 2005 Feb; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [Abstract] [Full Text] [Related]

  • 19. GH and mortality in acromegaly.
    Sheppard MC.
    J Endocrinol Invest; 2005 Feb; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [Abstract] [Full Text] [Related]

  • 20. Use of the oral glucose tolerance test to define remission in acromegaly.
    Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C.
    Metabolism; 2003 Feb; 52(2):181-5. PubMed ID: 12601629
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 32.